Get to know our clinical trials
Trial of JNJ-64042056, an active immunotherapy directed against phosphorylated tau in participants with preclinical Alzheimer's disease.
THE PURPOSE OF THIS STUDY IS TO EVALUATE THE SAFETY AND EFFICACY OF JNJ-64042056 IN SLOWING THE PROGRESSION OF ALZHEIMER'S DISEASE (AD) IN INDIVIDUALS WITH PRECLINICAL AD. HAVING PRECLINICAL ALZHEIMER'S DISEASE MEANS BEING IN AN EARLY STAGE OF THE DISEASE IN WHICH SIGNS OF MEMORY PROBLEMS ARE NOT YET APPARENT. AT THIS STAGE, ELEVATED LEVELS OF ABNORMAL PROTEINS (AMYLOID AND TAU) MAY BE DETECTED IN THE BLOOD, CEREBROSPINAL FLUID OR ON A PET SCAN.
Technical Summary
- MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY AND IMMUNOGENICITY OF JNJ-64042056, AN ACTIVE IMMUNOTHERAPY DIRECTED AGAINST PHOSPHORYLATED TAU IN PARTICIPANTS WITH PRECLINICAL ALZHEIMER'S DISEASE.
- Code EudraCT: 2023-505096-68-00
- Protocol number: 64042056ALZ2001
- Promoter: Janssen Research & Development
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.